溶瘤病毒促进肿瘤细胞自噬的研究进展

张凯; 刘滨磊; 柯亨宁

doi:10.3969/j.issn.1000-8179.2019.18.059

溶瘤病毒促进肿瘤细胞自噬的研究进展

doi: 10.3969/j.issn.1000-8179.2019.18.059

张凯^①,,
刘滨磊^②,
柯亨宁^{①, ③, ,}

①.
武汉大学中南医院感染科, 湖北省艾滋病临床指导培训中心(武汉市 430071)
②.
湖北工业大学生物工程与食品学院, 教育部"细胞调控与分子药物学科创新与引智基地"(111基地), 发酵工程教育部重点实验室
③.
宁夏医科大学总医院

基金项目:

国家自然科学基金项目 31760263

详细信息

作者简介:
张凯专业方向为感染性疾病的诊治与研究。E-mail:542461976@qq.com

通讯作者:
柯亨宁 kehengning@znhospital.cn

计量
- 文章访问数: 55
- HTML全文浏览量: 70
- PDF下载量: 9
- 被引次数: 0
出版历程
- 收稿日期: 2019-09-13
- 刊出日期: 2019-09-30

Research advances of oncolytic viruses promoting autophage in tumor cells

Zhang Kai^{①
,},
Liu BinLei^②,
Ke Hengning^{①, ③
, ,}

①.
Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Training Center of AIDS Prevention and Cure of Hubei Province, Wuhan 430071, China
②.
School of Food and Biological Engineering, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering(Ministry of Education), Hubei University of Technology, Wuhan 430068, China
③.
General Hospital, Ningxia Medical University, Yinchuan 750001, China

Funds:

the National Natural Science Foundation of Chin 31760263

More Information

Corresponding author: Hengning Ke; E-mail:kehengning@znhospital.cn

摘要

摘要: 自噬是一种正常的细胞生理活动，当正常细胞内存在异常蛋白、损坏的细胞器或处于饥饿状态时被激活，蛋白质和细胞器被捕获后送入到溶酶体降解，再将降解产物作为新合成蛋白和细胞器的底物加以循环利用，从而维持细胞内的平衡；溶瘤病毒（oncolytic virus，OV）是自然存在的或由人工生物技术合成的具有高度肿瘤靶向性及溶瘤性等特点的病毒。作为一种新颖的抗癌治疗方法其作用机制尚未明确。近年来研究发现OV引起肿瘤细胞死亡涉及到细胞自噬相关的机制。为了推进利用OV作为抗癌药物的研制，本文就OV诱导肿瘤细胞发生自噬的机制予以综述。
- 自噬 /
- 溶瘤病毒 /
- 肿瘤细胞
Abstract: Autophagy is a physiological process of normal cells that is activated in response to accumulation of abnormal proteins, damaged organelles, and cell starvation and involves their transport to lysosomes for degradation and recycling, enabling the maintenance of cellular homeostasis. Oncolytic viruses, which are obtained from naturally occurring or genetically modified viruses, specifically target and kill tumor cells. Despite receiving much attention, the mechanisms underlying this process remain unclear, although recent studies have implicated autophagy in the phenomenon. Here we outline how oncolytic viruses cause cell death via autophagy and how they can be exploited for the treatment of cancer.
- autophage /
- oncolytic virus /
- tumor cell

HTML全文

图 1 溶瘤病毒引起细胞自噬的途径

下载: 全尺寸图片幻灯片

参考文献(42)

[1]	Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses:a new class of immunotherapy drugs[J]. Nat Rev Drug Discov, 2015, 14(9):642-662. doi: 10.1038/nrd4663
[2]	Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer[J]. Nat Med, 2000, 6(8):879-885. doi: 10.1038/78638
[3]	Koks CA, De Vleeschouwer S, Graf N, et al. Immune suppression during oncolytic virotherapy for high-grade glioma; Yes or No[J]? J Cancer, 2015, 6(3):203-217. doi: 10.7150/jca.10640
[4]	Wing A, Fajardo CA, Avery D, et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager[J]. Cancer Immunol Res, 2018, 6(5):605-616. doi: 10.1158/2326-6066.CIR-17-0314
[5]	Khaled YS, Wright K, Melcher A, et al. Anti-cancer effects of oncolytic viral therapy combined with photodynamic therapy in human pancreatic cancer cell lines[J]. Lancet, 2015, 385(Suppl 1):S56. http://cn.bing.com/academic/profile?id=f15d13de0a4f2753158595e639b6937e&encoded=0&v=paper_preview&mkt=zh-cn
[6]	Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma[J]. J Clin Oncol, 2015, 33(25):2780-2788. doi: 10.1200/JCO.2014.58.3377
[7]	Levine B, Kroemer G. Autophagy in the pathogenesis of disease[J]. Cell, 2008, 132(1):27-42. doi: 10.1016/j.cell.2007.12.018
[8]	White E, Mehnert JM, Chan CS. Autophagy, metabolism, and cancer[J]. Clin Cancer Res, 2015, 21(22):5037-5046. doi: 10.1158/1078-0432.CCR-15-0490
[9]	Mukhopadhyay S, Panda PK, Sinha N, et al. Autophagy and apoptosis:where do they meet[J]? Apoptosis, 2014, 19(4):555-566. doi: 10.1007/s10495-014-0967-2
[10]	Garofalo M, Iovine B, Kuryk L, et al. Oncolytic adenovirus loaded with L-carnosine as novel strategy to enhance the antitumor activity[J]. Mol Cancer Ther, 2016, 15(4):651-660. doi: 10.1158/1535-7163.MCT-15-0559
[11]	Zhao Y, Li H, Wu R, et al. Antitumor effects of oncolytic adenoviruscarrying siRNA targeting potential oncogene EphA3[J]. PLoS One, 2015, 10(5):e126726. http://cn.bing.com/academic/profile?id=d378a8d7f9281f38a236b6a88182f116&encoded=0&v=paper_preview&mkt=zh-cn
[12]	Hu L, Sun S, Wang T, et al. Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy[J]. Am J Cancer Res, 2015, 5(12):3612-3623. http://cn.bing.com/academic/profile?id=3f25eb80bddd47b31f986dd5108b10f4&encoded=0&v=paper_preview&mkt=zh-cn
[13]	Fu X, Tao L, Rivera A, et al. Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication[J]. Int J Cancer, 2011, 129(6):1503-1510. doi: 10.1002/ijc.25808
[14]	Zakaria C, Sean P, Hoang HD, et al. Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis[J]. PLoS Pathog, 2018, 14(8):e1007264. doi: 10.1371/journal.ppat.1007264
[15]	O'Shea C, Klupsch K, Choi S, et al. Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication[J]. EMBO J, 2005, 24(6):1211-1221. doi: 10.1038/sj.emboj.7600597
[16]	Kemp V, JC I, Ronald W, et al. Oncolytic reovirus infection is facilitated by the autophagic machinery[J]. Viruses, 2017, 9(10):1-15.
[17]	Jiang H, White EJ, Gomez-Manzano C, et al. Adenovirus's last trick:you say lysis, we say autophagy[J]. Autophagy, 2008, 4(1):118-120. doi: 10.4161/auto.5260
[18]	Olagnier D, Lababidi RR, Hadj SB, et al. Activation of Nrf2 signaling augments vesicular stomatitis virus oncolysis via autophagy-driven suppression of antiviral immunity[J]. Mol Ther, 2017, 25(8):1900-1916. doi: 10.1016/j.ymthe.2017.04.022
[19]	Meng S, Xu J, Wu Y, et al. Targeting autophagy to enhance oncolytic virus-based cancer therapy[J]. Expert Opin Biol Ther, 2013, 13(6):863-873. doi: 10.1517/14712598.2013.774365
[20]	Bu XF, Wang MB, Zhang ZJ, et al. Autophagy is involved in recombinant Newcastle disease virus (rL-RVG)-induced cell death of stomach adenocarcinoma cells in vitro[J]. Int J Oncol, 2015, 47(2):679-689. doi: 10.3892/ijo.2015.3039
[21]	Tong Y, You L, Liu H, et al. Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia[J]. Oncotarget, 2013, 4(6):860-874. http://d.old.wanfangdata.com.cn/Conference/8671195
[22]	Jiang K, Li Y, Zhu Q, et al. Pharmacological modulation of autophagy enhances newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells[J]. BMC Cancer, 2014, 14(1):551. doi: 10.1186/1471-2407-14-551
[23]	Yin HC. Interactions between autophagy and DNA viruses[J]. Viruses, 2019, 11(9):539-546.
[24]	Wei J. Enhancing oncolytic immunotherapy through induction of immunogenic cell death[D]. 2019.
[25]	Lin LT, Dawson PW, Richardson CD. Viral interactions with macroautophagy:a double-edged sword[J]. Virology, 2010, 402(1):1-10. http://cn.bing.com/academic/profile?id=f6cee3b95b800c67b62470e89054f25c&encoded=0&v=paper_preview&mkt=zh-cn
[26]	Germic N, Frangez Z, Yousefi S, et al. Regulation of the innate immune system by autophagy:monocytes, macrophages, dendritic cells and antigen presentation[J]. Cell Death Differ, 2019, 26(4):715-727. doi: 10.1038/s41418-019-0297-6
[27]	Samuel S, Beljanski V, Van Grevenynghe J, et al. BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis[J]. Mol Ther, 2013, 21(7):1413-1423. doi: 10.1038/mt.2013.91
[28]	Bu X, Zhao Y, Zhang Z, et al. Recombinant newcastle disease virus (rLRVG) triggers autophagy and apoptosis in gastric carcinoma cells by inducing ER stress[J]. Am J Cancer Res, 2016, 6(5):924-936. http://cn.bing.com/academic/profile?id=5aebd69f73bbfec27807d6d6d8c743d1&encoded=0&v=paper_preview&mkt=zh-cn
[29]	Klein SR, Piya S, Lu Z, et al. C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy[J]. Oncogene, 2015, 34(41):5295-5301. doi: 10.1038/onc.2014.452
[30]	Jin J, Liu H, Yang C, et al. Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL:in vitro and in vivo evaluation[J]. Mol Cancer Ther, 2009, 8(5):1387-1397. http://cn.bing.com/academic/profile?id=b44213a26189d7903a34955f10aba237&encoded=0&v=paper_preview&mkt=zh-cn
[31]	Moscat J, Diaz-Meco MT. p62:a versatile multitasker takes on cancer[J]. Trends Biochem Sci, 2012, 37(6):230-236. doi: 10.1016/j.tibs.2012.02.008
[32]	Martinez-Velez N, Xipell E, Jauregui P, et al. The oncolytic adenovirus Delta24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity[J]. J Bone Miner Res, 2014, 29(10):2287-2296. doi: 10.1002/jbmr.2253
[33]	Lamark T, Svenning S, Johansen T. Regulation of selective autophagy:the p62/SQSTM1 paradigm[J]. Essays Biochem, 2017, 61(6):609-624. http://cn.bing.com/academic/profile?id=4dceb4c7414c5f278ac0d95c2b4b6e26&encoded=0&v=paper_preview&mkt=zh-cn
[34]	Xia M, Gonzalez P, Li C, et al. Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling[J]. J Virol, 2014, 88(9):5152-5164. doi: 10.1128/JVI.03851-13
[35]	Colunga A, Bollino D, Schech A, et al. Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to DeltaPK oncolytic activity in melanoma[J]. Gene Ther, 2014, 21(4):371-378. doi: 10.1038/gt.2014.6
[36]	Guo W, Song H. Development of gene therapeutics for head and neck cancer in China:rrom bench to bedside[J]. Hum Gene Ther, 2018, 29(2):180-187. doi: 10.1089/hum.2017.230
[37]	Burke JM, Lamm DL, Meng MV, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer[J]. J Urol, 2012, 188(6):2391-2397. doi: 10.1016/j.juro.2012.07.097
[38]	Delwar Z, Zhang K, Rennie PS, et al. Oncolytic virotherapy for urological cancers[J]. Nat Rev Urol, 2016, 13(6):334-352. doi: 10.1038/nrurol.2016.84
[39]	Lang FF, Conrad C, Gomez-Manzano C, et al. PhaseⅠstudy of DNX-2401(Delta-24-RGD) oncolytic adenovirus:replication and immunotherapeutic effects in recurrent malignant glioma[J]. J Clin Oncol, 2018, 36(14):1419-1427. doi: 10.1200/JCO.2017.75.8219
[40]	Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer[J]. Nat Med, 2013, 19(3):329-336. doi: 10.1038/nm.3089
[41]	Noonan AM, Farren MR, Geyer SM, et al. Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma[J]. Mol Ther, 2016, 24(6):1150-1158. doi: 10.1038/mt.2016.66
[42]	Greig SL. Talimogene laherparepvec:first global approval[J]. Drugs, 2016, 76(1):147-154. http://cn.bing.com/academic/profile?id=2acf765672bf90f9346224a660de7e95&encoded=0&v=paper_preview&mkt=zh-cn